Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Papp

Showing results (61-70 of 137) with videos related to

Pageof 14
Sort By:
Clinical Therapeutics|March 2, 2006
An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapyBernard Goffe, Kim Papp, David Gratton, et al.
Journal of the American Academy of Dermatology|February 21, 2006
Relapse, rebound, and psoriasis adverse events: an advisory group reportWayne Carey, Scott Glazer, Alice B Gottlieb, et al.
Cutis|September 1, 2011
An open-label, multicenter study of the efficacy and safety of an AM/PM treatment regimen with clobetasol propionate spray 0.05% and calcitriol ointment 3 microg/g in the management of plaque psoriasisAlan Menter, Howard Sofen, Stacy Smith, et al.
Journal of Cutaneous Medicine and Surgery|January 8, 2010
Update on alefacept safetyDenise Wexler, Gordon Searles, Ian Landells, et al.
Cutis|November 24, 2011
An open-label, multicenter study of the efficacy and safety of a weekday/weekend treatment regimen with calcitriol ointment 3 microg/g and clobetasol propionate spray 0.05% in the management of plaque psoriasisCharles P Hudson, Steven Kempers, Alan Menter, et al.
Rheumatology (Oxford, England)|October 25, 2022
Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 studyLars Erik Kristensen, Mauro Keiserman, Kim Papp, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|August 31, 2017
Management of chronic spontaneous urticaria (CSU): a treat to target approach using a patient reported outcomeHermenio Lima, Melinda Gooderham, Jan Dutz, et al.
Journal of Cutaneous Medicine and Surgery|November 22, 2017
Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 InhibitionRobert Bissonnette, Marc Bourcier, Melinda Gooderham, et al.
Journal of Cutaneous Medicine and Surgery|May 4, 2005
Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004Lyn Guenther, Richard G Langley, Neil H Shear, et al.
Journal of Cutaneous Medicine and Surgery|September 17, 2016
Review of Systemic Treatment Options for Adult Atopic DermatitisMelinda Gooderham, Charles W Lynde, Kim Papp, et al.
Pageof 14

Showing results (61-70 of 137) with videos related to

Sort By:
Pageof 14
Clinical Therapeutics|March 2, 2006
An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapyBernard Goffe, Kim Papp, David Gratton, et al.
Journal of the American Academy of Dermatology|February 21, 2006
Relapse, rebound, and psoriasis adverse events: an advisory group reportWayne Carey, Scott Glazer, Alice B Gottlieb, et al.
Cutis|September 1, 2011
An open-label, multicenter study of the efficacy and safety of an AM/PM treatment regimen with clobetasol propionate spray 0.05% and calcitriol ointment 3 microg/g in the management of plaque psoriasisAlan Menter, Howard Sofen, Stacy Smith, et al.
Journal of Cutaneous Medicine and Surgery|January 8, 2010
Update on alefacept safetyDenise Wexler, Gordon Searles, Ian Landells, et al.
Cutis|November 24, 2011
An open-label, multicenter study of the efficacy and safety of a weekday/weekend treatment regimen with calcitriol ointment 3 microg/g and clobetasol propionate spray 0.05% in the management of plaque psoriasisCharles P Hudson, Steven Kempers, Alan Menter, et al.
Rheumatology (Oxford, England)|October 25, 2022
Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 studyLars Erik Kristensen, Mauro Keiserman, Kim Papp, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|August 31, 2017
Management of chronic spontaneous urticaria (CSU): a treat to target approach using a patient reported outcomeHermenio Lima, Melinda Gooderham, Jan Dutz, et al.
Journal of Cutaneous Medicine and Surgery|November 22, 2017
Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 InhibitionRobert Bissonnette, Marc Bourcier, Melinda Gooderham, et al.
Journal of Cutaneous Medicine and Surgery|May 4, 2005
Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004Lyn Guenther, Richard G Langley, Neil H Shear, et al.
Journal of Cutaneous Medicine and Surgery|September 17, 2016
Review of Systemic Treatment Options for Adult Atopic DermatitisMelinda Gooderham, Charles W Lynde, Kim Papp, et al.
Pageof 14